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After taking 35 tablets of ﬂurazepam
15 mg, 50 tablets of diazepam 5 mg,
a 38-year old female (105 kg, BMI
36) was hit by a vehicle at 80 km/h.
Initially she had a coma that mea-
sured a 1-4-2 on the Glasgow Coma
Scale (GCS), an impression fracture
of the frontal bone with free air in
cerebro, a right-sided frontal contu-
sion and a mild traumatic
subarachnoidal bleed. Several ribs on
her right were broken without any
injury to the organs. After a decom-
pressive craniotomy, she was
admitted to the ICU.
At the time of admission, ﬂuraze-
pam (124 lg/L; therapeutic range 40–
150 lg/L [1, 2]) and diazepam serum
levels were therapeutic (439 lg/L;
therapeutic range 100–750 lg/L
[1, 2]). The active metabolite of diaz-
epam, desmethyldiazepam, was toxic
(5,971 lg/L; therapeutic range: 200–
1,800 lg/L[2]).Theothermetabolites
temazepam and oxazepam were low.
Fentanyl and propofol, adminis-
tered for analgesia and sedation, were
stopped after 2 days; the patient
received no other medication. A CT
cerebrum was repeated on day 5 and
revealed diffuse contusions. An elec-
troencephalogram indicated diffuse
encephalopathy. These ﬁndings were
considered insufﬁcient to explain her
persistent coma. Desmethyldiazepam
serum level remained high, despite
the patients’ normal liver and kidney
function. Flumazenil was adminis-
tered, revealing a coma ofof 4-3-T on
the GCS. As elimination of des-
methyldiazepam seemed to be
impaired, genotyping was performed.
This revealed that she was an exten-
sive cytochrome P450 (CYP) 2C19
metaboliser. To enhance elimination,
rifampicin, a CYP3A4 and 2C19
inducer, 600 mg bid i.v., was started
on day 12 (Fig. 1).
When the serum level of des-
methyldiazepam had fallen within
therapeutic ranges at day 20, the
patient improved. After 34 days she
was transferred to a neurological
medium care facility. Four months
after her hospital discharge, she had a
maximal GCS and was still recover-
ing from her injuries.
This case underscores two points.
First, diazepam and its active metab-
olites can considerably prolong coma.
This is due to the metabolic pathway
of diazepam [6]. Diazepam is
metabolized through CYP3A4 to
temazepam and CYP3A4/2C19 to
desmethyldiazepam which is then
metabolized through CYP3A4 to
oxazepam. Temazepam and oxaze-
pam, which have a small effect
compared to diazepam and des-
methyldiazepam are eliminated
through conjugation. The high levels
of desmethyldiazepam and low levels
of temazepam and oxazepam under-
score impairment of CYP3A4/2C19.
In benzodiazepine intoxications,
focus on withdrawal and clearance of
all active metabolites is advisable.
Second, rifampicin accelerated
clearance of the metabolites through
induction of CYP2C19 and CYP3A4.
Fig. 1 Time course of benzodiazepine serum levels before and during rifampicin
administration (fen fentanyl). Except for a brief period directly after ICU-admission, the
patient received no benzodiazepines or other sedatives, narcotics or analgesics. Due to high
levels and a challenge with Flumazenil demonstrated benzodiazepine intoxication,
rifampicin was started. After start of rifampicin, clearance of the metabolites was
accelerated, as indicated by the increasing decline of the metabolite concentration curves
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methyldiazepam decreased from
194 h (normal range 40–200 h [5]) to
63 after start of rifampicin and may
have shortened the comatose condi-
tion by 20 days. We preferred to use
rifampicin for several reasons. Rif-
ampicin is a well-characterised drug
with established strong CYP3A4/
2C19 inducing capabilities. Further-
more, the FDA [3, 4] considers
rifampicin as the drug of choice for
CYP450 inducer studies. Finally,
other CYP3A4 inducers like antiret-
roviral agents and anti-epileptics have
shortcomings like the advisable
restricted use for HIV treatment and
neurological side effects that could
have complicated assessment of our
patient or even provoked convulsions.
We suggest that rifampicin may be
considered in severe benzodiazepine
intoxications if clearance of the drug
appears to be problematic. Obviously,
other drug interactions and develop-
ment of rifampicin resistance should
be kept in mind.
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